Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 96, Issue 4, 2001, Pages 969-974

  Tefera, Solomon ^a   Hatlebakk, Jan Gunnar ^a   Berstad, Arnold ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG TOLERANCE; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HEALING; HEARTBURN; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; RELAPSE; STOMACH ACID SECRETION; STOMACH PH; SYMPTOMATOLOGY; TACHYPHYLAXIS;

ADOLESCENT; ADULT; AGED; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; H(+)-K(+)-EXCHANGING ATPASE; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; TACHYPHYLAXIS; TIME FACTORS;

EID: 0035050317     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02242-0     Document Type: Article

References (26)

1. Review article: Drug therapy for reflux oesophagitis
2. Gastro-esophageal reflux during three months of therapy with ranitidine in reflux esophagitis
3. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine
4. Tolerance during 8 days of high-dose H2-blockade: Placebo-controlled studies of 24-hour acidity and gastrin
5. Loss of acid suppression during dosing with H2-receptor antagonists
6. Tolerance to oral H2-receptor antagonists
7. Comparison of acid inhibition of either oral high-dose ranitidine or omeprazole
8. Twenty-four-hour intragastric pH: Tolerance within 5 days of continuous ranitidine administration
9. Lanzoprazole 15 mg and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis
10. Marked increase in gastric acid secretory capacity after omeprazole treatment
11. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status
12. Long-term omeprazole therapy in patients with Barrett's esophagus is associated with parietal cell hyperplasia
13. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis
14. Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway
15. Ambulatory 24 hour intraesophageal pH-monitoring in the diagnosis of gastroesophageal reflux disease
16. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety
17. Epidemiology and natural history of reflux esophagitis
18. Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump
19. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: A meta-analysis of long-term omeprazole trails
20. Fate of antacid gel in the stomach. Site of action and interaction with food
21. Relative stimulatory effects of commonly ingested beverages on gastric acid secration in humans
22. The timing of the evening meal affects the pattern of 24-hour intragastric acidity
23. Reproducibility of ambulatory gastric pH recordings in the corpus and antrum
24. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole
25. Effect of curing Helicobacter pylori infection on intragastric pH during omeprazole treatment
26. Helicobacter pylori augments the pH-raising effect of omeprazole in duodenal ulcer patients